Contact
searchSearch
HMP Global
Login
Conference Coverage
Concurrent Durvalumab With Chemoradiotherapy Did Not Improve Outcomes Among Patients With Unresectable Stage III NSCLC
09/08/2025
Allison Casey
Starting durvalumab concurrent with chemoradiotherapy and continuing as consolidation did not improve OS for patients with unresectable stage III non-small cell lung cancer.
Starting durvalumab concurrent with chemoradiotherapy and continuing as consolidation did not improve OS for patients with unresectable stage III non-small cell lung cancer.
Starting durvalumab concurrent...
09/08/2025
Oncology
Conference Coverage
Zidesamtinib for Patients With ROS1-Positive Advanced NSCLC
09/08/2025
Allison Casey
Zidesamtinib showed clinically meaningful activity and durability among patients with advanced ROS1-positive non-small cell lung cancer.
Zidesamtinib showed clinically meaningful activity and durability among patients with advanced ROS1-positive non-small cell lung cancer.
Zidesamtinib showed clinically...
09/08/2025
Oncology
Conference Coverage
Aumolertinib Plus Chemotherapy for Advanced NSCLC With EGFR and Tumor Suppression Gene Mutations
09/08/2025
Allison Casey
According to the phase 3 ACROSS study, aumolertinib plus chemotherapy improved progression-free survival among patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations with tumor suppression gene mutations.
According to the phase 3 ACROSS study, aumolertinib plus chemotherapy improved progression-free survival among patients with advanced non-small cell lung cancer harboring EGFR sensitizing mutations with tumor suppression gene mutations.
According to the phase 3 ACROSS...
09/08/2025
Oncology
Conference Coverage
Osimertinib Plus Chemotherapy as First-Line Standard-of-Care for Advanced EGFR-Mutant Non-Small Cell Lung Cancer
09/08/2025
Allison Casey
According to the phase 3 FLAURA2 study, osimertinib plus chemotherapy showed a statistically significant and clinically meaningful improvement to overall survival among patients with EGFR-mutant advanced non-small cell lung cancer.
According to the phase 3 FLAURA2 study, osimertinib plus chemotherapy showed a statistically significant and clinically meaningful improvement to overall survival among patients with EGFR-mutant advanced non-small cell lung cancer.
According to the phase 3 FLAURA2...
09/08/2025
Oncology
Conference Coverage
TROP2 Evaluation by Quantitative Continuous Scoring Among Patients With Non-Small Cell Lung Cancer
09/05/2025
Allison Casey
TROP2 evaluation among patients with NSCLC by quantitative continuous scoring was found to be reproducible across pathologists and serves as a robust approach for the real-world setting.
TROP2 evaluation among patients with NSCLC by quantitative continuous scoring was found to be reproducible across pathologists and serves as a robust approach for the real-world setting.
TROP2 evaluation among patients...
09/05/2025
Oncology
Conference Coverage
MET Positivity Not Predictive of Response to Amivantamab-Based Therapy Among Patients With EGFR-Mutant Lung Cancer
09/02/2025
Allison Casey
MET positivity was not validated as a biomarker for response to treatment with amivantamab-based treatment among patients with EGFR-mutant non-small cell lung cancer.
MET positivity was not validated as a biomarker for response to treatment with amivantamab-based treatment among patients with EGFR-mutant non-small cell lung cancer.
MET positivity was not validated...
09/02/2025
Oncology
Conference Coverage
Novel Whole Genome Sequencing Assay Demonstrates Promise in Detecting Ultrasensitive MRD Among Patients With Early-Stage Non-Small Cell Lung Cancer
09/02/2025
Stephanie Holland
Study results demonstrated that the use of a novel whole genome sequencing tumor-informed assay provided greater ultrasensitive molecular residual disease detection compared to historical controls with a first-generation assay among patients...
Study results demonstrated that the use of a novel whole genome sequencing tumor-informed assay provided greater ultrasensitive molecular residual disease detection compared to historical controls with a first-generation assay among patients...
Study results demonstrated that...
09/02/2025
Oncology
Conference Coverage
Molecular Residual Disease Assay May Predict Outcomes for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/02/2025
Stephanie Holland
According to a pre-specified exploratory analysis from the phase 3 NeoADAURA trial, baseline MRD status was found to be prognostic for clinical outcomes and pre-surgical MRD-negativity and clearance were associated with major pathological...
According to a pre-specified exploratory analysis from the phase 3 NeoADAURA trial, baseline MRD status was found to be prognostic for clinical outcomes and pre-surgical MRD-negativity and clearance were associated with major pathological...
According to a pre-specified...
09/02/2025
Oncology
Sally Lau, MD
Videos
Tarlatamab Plus PD-L1 Inhibitor as Potential First-Line Maintenance for Extensive-Stage Small Cell Lung Cancer
10/08/2024
Sally Lau, MD
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results from the phase 1b DeLLphi-303 study which demonstrated that tarlatamab plus a PD-L1 inhibitor exhibited efficacy as a first-line maintenance therapy for patients with extensive-stage small cell lung cancer.
Sally Lau, MD, discusses results...
10/08/2024
Oncology
Conference Coverage
Durvalumab With Chemotherapy And Novel Agents for Early-Stage, Resectable Non-Small Cell Lung Cancer
09/11/2024
Allison Casey
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found durvalumab, single-agent platinum chemotherapy, and datopotamab deruxtecan to yield the highest pCR rate among patients with early-stage resectable non-small cell lung cancer, when compared to other combinations.
The NeoCOAST-2 trial found...
09/11/2024
Oncology
Conference Coverage
Ivonescimab As New First-Line Treatment Option for Patients with PD-L1–Positive, Advanced Non-Small Cell Lung Cancer
09/09/2024
Allison Casey
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically meaningful and statistically significant improvement to progression-free survival for patients with PD-L1–positive, advanced non-small cell lung cancer, when compared with pembrolizumab.
Ivonescimab showed a clinically...
09/09/2024
Oncology
Conference Coverage
Addition of Anlotinb to Durvalumab Maintenance Improved Survival Results Among Patients With Extensive-Stage Small Cell Lung Cancer
09/09/2024
Stephanie Holland
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE trial demonstrated that durvalumab plus anlotinib in the maintenance setting improved survival results compared to durvalumab alone among patients with extensive-stage small cell lung cancer.
Results from the phase 2 DURABLE...
09/09/2024
Oncology
Conference Coverage
Sacituzumab Govetican Shows Promise for Second-Line Extensive-Stage Small Cell Lung Cancer
09/05/2024
Allison Casey
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results from the TROPiCS-03 trial, sacituzumab govetican showed promising antitumor activity among patients with both platinum-resistant and platinum-sensitive extensive-stage small cell lung cancer in the second-line...
According to updated results...
09/05/2024
Oncology
Alexander Spira, MD, PhD
Videos
Antitumor Activity of Amivantamab Among Patients With METex14 Non-Small Cell Lung Cancer
09/13/2023
Alexander Spira, MD, PhD
Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.
Alexander Spira, MD, PhD, discusses the efficacy of amivantamab among patients with METex14 NSCLC enrolled in the CHRYSALIS study, as presented at the 2023 World Conference on Lung Cancer.
Alexander Spira, MD, PhD,...
09/13/2023
Oncology
Alexander Spira, MD, PhD
Videos
Amivantamab, Lazertinib, and Chemotherapy Quadruplet Therapy Demonstrated Durable Response Among Patients With EGFR-Mutated Non-Small Cell Lung Cancer
09/13/2023
Alexander Spira, MD, PhD
Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...
Alexander Spira, MD, PhD, discusses updated results from the CHRYSALIS-2 study, in which amivantamab and lazertinib plus chemotherapy demonstrated durable and meaningful responses among patients with EGFR-mutated NSCLC, as presented at the...
Alexander Spira, MD, PhD,...
09/13/2023
Oncology
Tetsuya Mitsudomi, MD, PhD
Videos
Addition of Perioperative Durvalumab to Neoadjuvant Chemotherapy Did Not Adversely Affect Surgical Outcomes Among Patients With Resectable Non-Small Cell Lung Cancer
09/12/2023
Tetsuya Mitsudomi, MD, PhD
At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...
At the 2023 World Conference on Lung Cancer, Tetsuya Mitsudomi, MD, PhD, presented results which demonstrated the addition of perioperative durvalumab to neoadjuvant chemotherapy did not adversely affect surgical outcomes among patients with...
At the 2023 World Conference on...
09/12/2023
Oncology
Conference Coverage
Toripalimab With First-Line Chemotherapy Yields Superiority in Advanced NSCLC
09/13/2021
Data from the CHOICE-01 phase 3 trial confirm that toripalimab in combination with first-line chemotherapy showed superior PFS, ORR, and DOR, with a manageable safety profile in patients with advanced NSCLC.
Data from the CHOICE-01 phase 3 trial confirm that toripalimab in combination with first-line chemotherapy showed superior PFS, ORR, and DOR, with a manageable safety profile in patients with advanced NSCLC.
Data from the CHOICE-01 phase 3...
09/13/2021
Oncology
Conference Coverage
Camrelizumab Plus Apatinib Yields Promising Activity in Advanced NSCLC
09/13/2021
Results of a phase 2 trial reveal promising clinical activity for camrelizumab plus apatinib as a combination treatment in the frontline setting for patients with non-squamous NSCLC at the virtual 2021 World Conference on Lung Cancer.
Results of a phase 2 trial reveal promising clinical activity for camrelizumab plus apatinib as a combination treatment in the frontline setting for patients with non-squamous NSCLC at the virtual 2021 World Conference on Lung Cancer.
Results of a phase 2 trial...
09/13/2021
Oncology
Dr Spira
Videos
Dr Spira Highlights Amivantamab as Promising Treatment in METex14 Mutated NSCLC
09/10/2021
Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...
Alexander Spira, MD, PhD, FACP, discusses new evidence supporting the use of the amivantamab in the treatment of patients with NSCLC with MET exon 14 skipping (METex14) mutations, to be presented at the IASLC 2021 World Conference on Lung...
Alexander Spira, MD, PhD, FACP,...
09/10/2021
Oncology
Conference Coverage
Greater Immune Protection Against SARS-CoV-2 Needed in Lung Cancer Therapy
09/10/2021
An ongoing cohort study found that although most lung cancer patients have displayed promising antibody responses to SARS-CoV-2 vaccinations, a subgroup exhibited significantly lower antibody/neutralizing levels, indicating further studies...
An ongoing cohort study found that although most lung cancer patients have displayed promising antibody responses to SARS-CoV-2 vaccinations, a subgroup exhibited significantly lower antibody/neutralizing levels, indicating further studies...
An ongoing cohort study found...
09/10/2021
Oncology
Conference Coverage
Real-World Data Shows Lurbinectedin Beneficial for Pretreated SCLC and Mesothelioma
09/10/2021
Lurbinectedin offers clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma, according to real-world data presented at the 2021 IASLC World Conference on Lung Cancer.
Lurbinectedin offers clinical benefit for heavily pretreated patients with small cell lung cancer and mesothelioma, according to real-world data presented at the 2021 IASLC World Conference on Lung Cancer.
Lurbinectedin offers clinical...
09/10/2021
Oncology

Experts from across the globe participate, discover, and share groundbreaking research in the IASLC 2021 World Conference on Lung Cancer of the International Association for the Study of lung Cancer.

Tracks

Lung Cancer

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use